Fluicell’s response to COVID-19
As the COVID-19 infection spreads across the world, many workplaces struggle to keep activities going while minimizing exposure…
First sale of Biopixlar and collaboration with University of Canterbury
We are proud to announce the first sale of the Biopixlar® platform to University of Canterbury, NZ. The…
03
Mar
2020
Promising new receptor modulator affecting cognitive dysfunction
The alpha-7 nicotinic receptor (nAChR) is an acetylcholine receptor with implied importance for long-term memory and with a…
03
Mar
2020
Biopixlar ready to face key challenges for bioprinting
As the world of bioprinting moves from concepts to actual biological applications, the performance requirements put on emerging…
13
Feb
2020
Fluicell at BPS 2020
Fluicell is an innovative biotech company with the ambition to create new opportunities for life science. This year,…
05
Feb
2020
Fluicell welcomes Klaudia Małgorzata Jurczak
Starting in January 2020, Klaudia Małgorzata Jurczak is joining Fluicell to do her Master’s thesis work. Klaudia has…
04
Feb
2020
NMDAR enhancer with benefits for Alzheimer´s disease
NMDA receptors play subunit-specific roles in synaptic function with connections to neuropsychiatric and neurodegenerative disorders. In the study…
28
Jan
2020
Student visit at Fluicell
Yesterday we had the great pleasure of receiving a student visit from SBE Student Chapter Chalmers. It was…
21
Jan
2020
Promising new insights into ion channel function
Researchers at Genentech Inc. have studied the structure and function of voltage-gated sodium channels, using Dynaflow Resolve to…
17
Dec
2019